VivoSeq
Other

Sexual Dysfunction

40

Pipeline Programs↗

3

Active Trials↗

21

Companies Involved↗

Sexual Dysfunction is a moderately active landscape with 40 programs across 21 companies. The most active players are Pfizer, Auxilium, GSK. 23 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 2A

Auxilium

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Q

QuatRx Pharmaceuticals Company

1 program

Phase 2Eli Lilly logo

Eli Lilly

3 programs

Phase 2Q

QualiLife Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

32

clinical trials

Completed19 · 59%
Unknown status5 · 16%
Terminated5 · 16%
Recruiting2 · 6%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

32 trials

Sexual Dysfunction in Hypertensive Women
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT05156385·348 enrolled
A Single-Blind, Randomized Study of the BTL Emsella Chair Versus Sham for the Treatment of Male Sexual Dysfunction
Recruiting·CCorewell Health East·Preclinical·NCT05370651·117 enrolled
Female Sexual Dysfunction Assessment and Managment of Vaginismus
Not yet recruiting·—·Phase 2/3·NCT06755099·40 enrolled
Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women
Completed·UUniversity of New Mexico·Phase 4·NCT00375297·100 enrolled
Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
Completed·Eli Lilly logoEli Lilly·N/A·NCT00561509·1,626 enrolled
Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
Completed·MMassachusetts General Hospital·Phase 3·NCT00568126·45 enrolled
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
Completed·Pfizer logoPfizer·Phase 2·NCT00479570·23 enrolled
Lybrido for Female Sexual Dysfunction
Completed·EEmotional Brain NY Inc.·Phase 2·NCT01432665·196 enrolled
ANDRO 2002: Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction
Completed·QQueen's University·Phase 2·NCT00202163·120 enrolled
Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00707187·120 enrolled
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00034021
the Ameliorating Effects of Antioxidant Gel on Female Arousal Disorder and Sexual Dysfunction
Completed·—·Phase 1·NCT06060691·30 enrolled
Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
Completed·WWright State University·N/A·NCT02865187·47 enrolled
BP101 for Adults With Female Sexual Dysfunction
Completed·IIvix LLX·Phase 3·NCT03463707·205 enrolled
Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo
Completed·SSt. Luke's-Roosevelt Hospital Center·Phase 4·NCT00334048·9 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)